clinical trial · NCT05891119
Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis
Amgen·early phase1·completed·n = 21
Atopic DermatitisCaffeineMetoprololMidazolamWarfarinVitamin KOmeprazoleRocatinlimab
brief summary
The primary objective of the study is to evaluate the pharmacokinetics (PK) of multiple cytochrome P450 (CYP450) substrates alone and in combination with rocatinlimab in participants with moderate to severe atopic dermatitis (AD).
started
Jun 3, 2023
primary completion
Aug 28, 2024
completion
Feb 12, 2025
last updated
Dec 23, 2025
official title
A Phase 1, Open-label, Drug-Drug Interaction Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple CYP450 Substrates in Patients With Moderate to Severe Atopic Dermatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol